Clinical Trial Update: METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating bone marrow-derived mononuclear cells for chronic ischemic heart disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Disease

Drugs mentioned

• bone marrow-derived mononuclear cells

Snippet

Sponsor: Cardiocentro Ticino | Conditions: Chronic Ischemic Heart Disease | Phase 1, Phase 2 | Status: TERMINATED